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Methods: We reviewed the clinical data of all patients
diagnosed with primary angiosarcoma of the heart, aorta,
and great vessels from 1985 to 2011, including presenta-
tion, diagnosis, management, and outcomes.
Results: Thirteen patients (5 males and 8 females;
mean age, 544 years) had primary angiosarcoma arising
from the aorta (n7), heart (n3), pericardium (n2),
and pulmonary artery (n1). Aortic tumors most com-
monly presented with lower extremity claudication (n4),
renovascular HTN (n3), abdominal pain (n5), and
weight loss (n4). Cardiac and pericardial tumors pre-
sented with dyspnea (n5) due to pleural effusion or
cardiac tamponade. All 13 patients underwent Com-
puted Tomography (CT) scan demonstrating irregular,
lobulated mass/thrombus with peripheral enhancement
and 8 patients had diagnostic echocardiogram. Meta-
static disease was present in 10 patients; most common
site was lungs (n6). All except one patient had high
grade sarcoma on pathology. Most common endothelial
antigen was CD31. Nine patients were treated surgically;
resection with aortic reconstruction (n6), thrombec-
tomy (n1), and pericardiectomy with patch (n2).
Adjunctive treatment included chemotherapy (n7) and
radiation (n4). Median survival was 8 months (range
1-75). Patients treated with all 3 treatment modalities
had longer survival than patients treated with a single
modality (P.013). Patients treated with chemotherapy
had a more favorable survival than those without chemo-
therapy (P.048).
Conclusions: Primary angiosarcoma of the heart and
great vessels is rare, but a harbinger of poor prognosis.
Endothelial antigen CD31 is diagnostic. Combined ther-
apy with surgical resection and chemoradiotherapy offer
patients the best survival.
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Objectives: To examine the outcomes of tibial endo-
vascular interventions with respect to ulcer healing and
prevention of major limb loss.
Methods: A database of patients between 2001 and
2011 was queried. Patients presenting with tissue loss
(Rutherford class 5 and 6) were selected. Immediate suc-
cess of the intervention was defined as healing of the
ulcer or a successful forefoot amputation after interven-
tion. Clinical efficacy was defined as absence of recurrent
symptoms, maintenance of ambulation and absence of
major amputation.
Results: : 248 limbs in 245 patients (60% male, mean
age 67) underwent tibial artery interventions for tissue loss.
68% had diabetes, 63% hyperlipidemia and 24% chronic
renal insufficiency. The mean patent tibial vessels at presen-
tation were 1.20.6 (SD). 76% of the tibial lesions were
TASC C. Technical success was 98% with a mean of 2
vessels treated per patient. 388 tibials were treated. Overall
mortality was 1% and overall morbidity was 14% at 90 days
after the procedure. 76% of ulcers healed after the interven-
tion at a mean of 9 months. 34% required either toe or
trans-metatarsal amputation, while 24% of the limbs under-
went major amputation. Cumulative patency was 685% at
five years. 31% of patients necessitated two or more re-
interventions. At 5 years, freedom from ulcer recurrence
and major limb amputations were 544% and 486%,
respectively. Clinical efficacy was 344% at 5 years. OnCox
proportional hazard analysis, greater tissue loss at presen-
tation, BMI30, diabetes, hemodialysis, low mobility at
presentation, higher tibial TASC lesion and poor pedal
runoff were associated with decreased ulcer healing and
lower limb salvage.
Conclusions: Tibial interventions do allow for ulcer
healing within one year with a lowmortality andmorbidity;
however, one in four patients will require a major amputa-
tion within 5 years.
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Objectives: Evaluate whether closure devices (CD) are
a safe method for preventing surgical complications associ-
ated with femoral access. As a secondary goal, the use of
ultrasound for femoral access and performance of an ade-
quate completion angiogram prior to CD deployment were
evaluated.
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 1S Abstracts 7S
